News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Treatment interruptions
Pegylated interferon may maintain HIV suppression and reduce viral DNA integration

Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.

Published
12 November 2012
From
HIVandHepatitis.com
New and experimental HIV treatments
Is protease inhibitor monotherapy sufficient to keep HIV under control in the brain?

Researchers in Sweden and Switzerland have been conducting clinical trials of PI monotherapy and HIV-related neurological research. Recently, two teams have separately reported that their data strongly suggest that injury to cells within the brain has occurred in some participants when exposed to PI monotherapy. The Swedish team recommends that PI monotherapy be used cautiously until further clinical trials are completed and more detailed information on the brain health of participants becomes available.

Published
02 November 2012
From
CATIE
HIV treatment
The generic generation

In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the

Published
22 October 2012
From
HIV treatment update
Treatment-experienced people
Booster HIV Drug Can Be Dropped

In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.

Published
13 September 2012
From
MedPage Today
Diabetes
Glucose metabolism worsens in HIV treatment-experienced taking NRTI-sparing regimens

Italian investigators have found evidence of worsening glucose tolerance in highly treatment-experienced HIV-positive patients treated with nucleoside-sparing regimens. The small study, which is published in the online edition

Published
24 August 2012
By
Michael Carter
Changing treatment
Are antiretroviral switch or simplification studies of benefit for patients?

The attitude of physicians, ethics committees and medical journals to antiretroviral switch and simplification studies needs to be radically reappraised, according to an article published in PLoS Medicine.

Published
15 August 2012
By
Michael Carter
Finance and funding
First generic HIV drugs could save US at least $920 million a year

Even using very conservative estimates of efficacy, using two generic HIV drugs plus one branded one in the most popular first-line regimen instead of using all three

Published
27 July 2012
By
Gus Cairns
Changing treatment
Second-line HIV therapy effective and durable in South Africa, and adherence support could improve rates of viral suppression

Second-line antiretroviral therapy in South Africa achieves durable viral suppression in three-quarters of patients and is associated with an increase in CD4 cell count, investigators report in

Published
27 June 2012
By
Michael Carter
Changing treatment
Big delays in switching to second-line ART in South Africa

Virologic rebound occurred in only one in six patients during the first 18 months of antiretroviral treatment at five major public hospitals in South Africa, according to an

Published
08 June 2012
By
Carole Leach-Lemens
Changing treatment
Treatment switches becoming less common, side-effects still the key reason for switching

The number of people who need to change their antiretroviral drug regimen has declined significantly in recent years, Alison Boyle of the Chelsea & Westminster Hospital, London

Published
24 April 2012
By
Roger Pebody
← Prev12345...21Next →

Filter by country